Terms ending in 2026
Every in-force patent on Sanofi's record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,008,310 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same In force · Medium confidence | Sanofi | In force | Medium confidence | |
| US 8,003,385 | In Vitro Germinal Centers In force · High confidence | Sanofi Pasteur Vaxdesign Corporation | In force | High confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.